Early Post Transplant Cardiac Allograft Vasculopathy — ECAV  

Cardiac Allograft Vasculopathy Clinical Trial

Official title: Early Post Transplant Cardiac Allograft Vasculopathy

Status Active, not recruiting

Clinical Trial Summary

Heart transplantation is an effective life-saving treatment for patients with end-stage heart disease. After a transplant, the new heart may develop narrowing in the arteries, causing heart failure, heart attacks and abnormal heart rhythms. This condition is known as cardiac allograft vasculopathy (CAV). The disease is very common, affecting almost a third of heart transplant patients by 5 years after transplant. CAV is a serious problem that causes the new heart to fail and is one of the main causes of death after transplant. Early detection of CAV is important as treatment options are poor once the disease is established. Currently, available techniques to evaluate CAV are limited by poor ability to detect disease early. The current tests usually focus on the large heart arteries and do not examine the smaller arteries that are also affected.

Clinical Trial Description

The objective of this study is to determine whether early abnormalities of the heart arteries after heart transplantation can predict the development of CAV. We will use a combination of sophisticated imaging tools to examine in detail the early changes that occur in the arteries of a new heart. Heart transplant patients from the University of Ottawa Heart Institute and Toronto General Hospital will undergo a series of tests at 3 and 12 months after transplant. Statistical analyses will determine whether results from the above tests at 3 months predict the development of early CAV at 12 months after a heart transplant. ;

Related Conditions & MeSH terms

• Cardiac Allograft Vasculopathy
• Vascular Diseases

• NCT number: NCT03217786
• Study type: Observational
• Source: Ottawa Heart Institute Research Corporation
• Status: Active, not recruiting
• Start date: February 12, 2018
• Completion date: September 2025